Artificial Intelligence for New Drug Design
A Technology Platform for Deep-Learning-Based de novo Drug Design
Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies. Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, Francebased start-up Iktos is developing a proprietary AI technology for ligand and structure-based de novo drug design, focusing on multi parametric optimization (MPO). Yann Gaston-Mathé, co-founder and CEO of Iktos, explains the company’s technologies and provides an outlook on the further development of the company.
No comments were found for Artificial Intelligence for New Drug Design. Be the first to comment!